Stockholm, Sweden, December 22, 2020. The Chairman of Egetis Therapeutics AB has established a Nomination Committee for the Annual General Meeting, which is planned to be held on April 29, 2021. The Nomination Committee is composed of members appointed by the three largest shareholders in terms of voting rights, that have accepted the invitation to join the committee.
The following members have been appointed by the subsequent shareholders:
Avla Holding AB: Kenneth Rooth
Fjärde AP-fonden: Jannis Kitsakis
Cidro Förvaltning AB: Peter Lindell
The Nomination Committee has elected Kenneth Rooth as chairman. Håkan Åström, Chairman of the Board of Directors, has been nominated to co-opt to the Nomination Committee.
In total, the Nomination Committee represents approx. 26% of the total number of shares and votes in the company. All representatives are independent in relation to the company and its executive management. Peter Lindell and Jannis Kitsakis are also independent in relation to Cetoros AB, which is the largest shareholder in the company in terms of votes but has declined participation in the committee.
The Committee's assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board´s members, to the Annual General Meeting (AGM). The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals regarding the process to appoint the Nomination Committee for the AGM in 2022.
Shareholders who wish to submit proposals to the Nomination Committee can do so by email: [email protected]
